{"title": "Bibliometric Analysis of Global Scientific Research on SARSCoV-2 (COVID-19)", "doi": "10.1101/2020.03.19.20038752", "citation_id": "2020.03.19.20038752v1", "date": "2020-03-23", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.19.20038752", "abstract": "<p>Background  and  Aim:  Since  late  2019,  an  unknown-origin  pneumonia  outbreak detected  in  Wuhan  city,  Hubei  Province,  China.  We  aimed  to  build  a  model  to qualitatively  and  quantitatively  assess  publications  of  research  of  COVID-19  from  2019 to  2020. Materials  and  Methods:  Data  were  obtained  from  the  Web  of  Science  (WOS), PubMed,  and  Scopus  Core  Collection  on  March  02,  2020,  and  updated  on  March  10. We  conducted  a  qualitative  and  quantitative  analysis  of  publication  outputs,  journals, authors,  institutions,  countries,  cited  references,  keywords,  and  terms  according  to bibliometric methods  using  VOS  viewer  c software packages.   Results:  Initially,  we  identified  227  papers,  of  which  after  an  exclusion  process,  92 studies  were  selected  for  statistical  analyses.  China  accounted  for  the  highest proportion  of  published  research  (44  papers,  40.48%), followed  by  the  United  States  (21 papers,  19.32%),  and  Canada  (7  papers,  6.44%).  Adjusted  by  gross  domestic  product (GDP),  ranked  first,  with  0.003  articles  per  billion  GDP.  In  total,  the  top  10  journals published  47  articles,  which  accounted  for  51.08%  of  all  publications  in  this  Feld.  A  total of  6  studies  (05.52%) were  supported  by  National  Natural  Science  Foundation  of  China.   Chinese  Academy  of  Sciences ranked  second  2,  2.76%). Conclusion:  Bibliometric  and  visualized  mapping  may  quantitatively  monitor  research performance  in  science  and  present  predictions.  The  subject  of  this  study  was  the  fast growing  publication  on  COVID-19.  Most  studies  are  published  in  journals  with  very  high impact  factors (IFs)  and  other journals are  more  interested  in  this type  of  research.</p>", "twitter_description": "Background and Aim: Since late 2019, an unknown-origin pneumonia outbreak detected in Wuhan city, Hubei Province, China. We aimed to build a model to qualitatively and quantitatively assess publications of research of COVID-19 from 2019 to 2020. Materials and Methods: Data were obtained from the Web of Science (WOS), PubMed, and Scopus Core Collection on March 02, 2020, and updated on March 10. We conducted a qualitative and quantitative analysis of publication outputs, journals, authors, institutions, countries, cited references, keywords, and terms according to bibliometric methods using VOS viewer c software packages. Results: Initially, we identified 227 papers, of which after an exclusion process, 92 studies were selected for statistical analyses. China accounted for the highest proportion of published research (44 papers, 40.48%), followed by the United States (21 papers, 19.32%), and Canada (7 papers, 6.44%). Adjusted by gross domestic product (GDP), ranked first, with 0.003 articles per billion GDP. In total, the top 10 journals published 47 articles, which accounted for 51.08% of all publications in this Feld. A total of 6 studies (05.52%) were supported by National Natural Science Foundation of China. Chinese Academy of Sciences ranked second 2, 2.76%). Conclusion: Bibliometric and visualized mapping may quantitatively monitor research performance in science and present predictions. The subject of this study was the fast growing publication on COVID-19. Most studies are published in journals with very high impact factors (IFs) and other journals are more interested in this type of research.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nNone\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data presented in the manuscript.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038752v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038752v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.19.20038752v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.19.20038752.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.19.20038752v1", "access_rights": "restricted", "authors": ["Fateme Rafiei Nasab", "Fakher rahim"]}